Clinical Trial Search

Primary: Patient-reported Symptom Response to Treatment Measured by the Reflux Symptom Index (RSI) Score — 15.5 score on a scale

Primary: CLINICAL OUTCOME OF FEEDING SUCCESS — 33; 44 percentage of participants — p=0.28

Primary: The Primary Symptom of GERD in Chinese Outpatients in Gastroenterology Department — 19; 30; 42; 23 Participants

Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00

Primary: Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study. — 34.3; 10.4 Percentage of participants

Primary: Number of Transient Lower Esophageal Sphincter Relaxations (TLESRs) 0-3 Hours Post Meal, Post Third Dose — 11.6; 15.5 Relaxations

Primary: Percent Change in the Reflux Symptom Index (RSI) at 4 Weeks — -54.3 Per Cent Change — p=<0.05

Primary: To Evaluate the Incidence of All Adverse Events at Various Time Points. — 29 participants

Primary: The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period…

Primary: The Number of Reflux in GERD Patients — 33.6; 42.8; 81.0; 53.1 episodes — p=0.002

Primary: TRPV1, GDNF, and NGF mRNA Expression of Esophageal Mucosa — 1.14; 3.25; 2.33; 1.39 Fold change

Primary: Change in Reflux Disease Questionnaire Scores Administered at Baseline and 6 Weeks After Each Intervention — -1.2397; 0.0869 scores on a scale — p=0.0002

Primary: Number of Participants Presenting Reflux Symptoms — 31; 8; 5 participants — p=<0.001

Primary: Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12…

Primary: Bradycardia Episodes/Day — 4.6; 3.6 episodes per day

Primary: Time to First Pulmonary Exacerbation — NA; NA Weeks

Primary: Changing Severity of Heart Burn of SSc Related Omeprazole Resistant GERD Evaluated by Visual Analogue Score (VAS) — 17.9; 17.2 VAS (100)

Primary: Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment — -3.44 Days per week with symptoms

Primary: Association of Change in Patient's GSR From Beginning to End of Study Visit With GERD Symptom Severity 2 Weeks Later — -0.94; -1.70 micro-Siemens — p=0.034

Primary: Forced Vital Capacity (FVC) — -0.13; -0.05 liters

Primary: Number of Participants in Each Level of Wheeze Control — 18; 11; 9 Participants

Primary: Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period. — 174; 166; 156 Participants

Primary: Number of Impedance Episodes Following PPI and Placebo — 47; 53 number of episodes

Primary: Change From Baseline in Percent Regurgitation-Free Days Over Weeks 5-8 — 36.96; 43.01; 44.37; 38.79 percentage of days — p=0.128

Primary: Change in Weekly Gastroesophageal Reflux Disease (GERD) Symptom Scores (WGSS) — -0.89; 0.02; -0.47; -1.11 units on scale — p=<0.001

Primary: Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los…

Primary: Patient's Assessment of Stanford Sleepiness Scale for the Last 24 Hours (Diaries) — 2.94; 2.62; 2.28; 2.03 Units on a scale

Primary: Number of Participants With at Most One Day With Not More Than Mild Intensity of the Symptoms 'a Burning Feeling Behind the Breastbone' and 'Unpleasant Movement of…

Primary: Gastroesophageal Reflux Disease Health Related Quality of Life Outcome (GERD-HRQL) — 4.2; 4.9 score on a scale

Primary: Treatment-emergent Adverse Events Experienced by >=5% of Patients in Any Treatment Group — 3; 2; 3; 2 Participants